Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk

Dow Jones

Mar 30

0958 GMT - Novo Nordisk's first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. "Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS." However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. JPM says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 30, 2026 05:59 ET (09:59 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2623151263"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623151263\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623151263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 17:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623151263","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0958 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. <a href=\"https://laohu8.com/S/JPM\">JPM</a> says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 05:59 ET (09:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-30 17:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0958 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. <a href=\"https://laohu8.com/S/JPM\">JPM</a> says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 05:59 ET (09:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOX","symbol_name":"2倍做多NVO ETF-Defiance","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2623151263","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623151263","pubTimestamp":1774864740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0958 GMT - Novo Nordisk's first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. JPM says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVOX":"2倍做多NVO ETF-Defiance","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股"},"translate_title":"诺和诺德盈利可能稳健，但共识仍然过高——市场传言","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVOX":0.6,"NVO":1.95},"content_text":"0958 GMT - Novo Nordisk's first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. JPM says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 05:59 ET (09:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}